Study of SYS6020 injection for active lupus
Part of Immune system & allergy clinical trials.
This trial tests a new medicine called SYS6020 given as an injection. It is for people with active lupus that hasn't improved with standard treatments. The goal is to see if it's safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 70 years old.
- You must have a confirmed diagnosis of systemic lupus erythematosus (SLE), often called lupus.
- Your lupus must be active despite taking standard medicines like steroids and immunosuppressants for at least 3 months.
- You must have certain antibodies in your blood (such as ANA, anti-dsDNA, or anti-Smith).
- You need to meet a minimum activity score (SLEDAI-2K of 7 or more) and other clinical activity measures.
- You cannot have severe lupus kidney problems or brain issues within the last 8 weeks, and you must not have used B-cell-targeting treatments recently.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new injection called ACG102 for people with lupus that has not improved with standard treatments. The goal is to see if it can help control active lupus symptoms.
This study tests a new injectable medicine (SG301) for people with lupus (SLE) whose current treatments are not working well enough or cause side effects. It aims to see if this targeted therapy can better control lupus symptoms.
This trial tests an investigational injection called CM313 for people with active lupus (systemic lupus erythematosus). It aims to see if the drug can help reduce lupus symptoms and control the disease.
This study tests a new investigational drug called SCTB35 for people with active systemic lupus erythematosus (SLE or lupus). It aims to see if the drug is safe and effective in controlling lupus activity when added to your current stable lupus medications.
This study tests an experimental injection called ZM001 for people with severe lupus that hasn't improved with standard treatments. The goal is to see if this new therapy can help control the disease.
This trial tests a new treatment for people with active lupus who haven't responded well to steroids and at least two other immune-suppressing drugs, including a biologic. It aims to find a better option for controlling lupus symptoms.
Hear when a new Refractory Active Systemic Lupus Erythematosus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.